Literature DB >> 30400719

Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30400719      PMCID: PMC6223128          DOI: 10.1002/ajh.25117

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  141 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.

Authors:  Meletios A Dimopoulos; Hartmut Goldschmidt; Ruben Niesvizky; Douglas Joshua; Wee-Joo Chng; Albert Oriol; Robert Z Orlowski; Heinz Ludwig; Thierry Facon; Roman Hajek; Katja Weisel; Vania Hungria; Leonard Minuk; Shibao Feng; Anita Zahlten-Kumeli; Amy S Kimball; Philippe Moreau
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

3.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

4.  Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authors:  Paul G Richardson; David S Siegel; Ravi Vij; Craig C Hofmeister; Rachid Baz; Sundar Jagannath; Christine Chen; Sagar Lonial; Andrzej Jakubowiak; Nizar Bahlis; Kevin Song; Andrew Belch; Noopur Raje; Chaim Shustik; Suzanne Lentzsch; Martha Lacy; Joseph Mikhael; Jeffrey Matous; David Vesole; Min Chen; Mohamed H Zaki; Christian Jacques; Zhinuan Yu; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-13       Impact factor: 22.113

5.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

Review 6.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

7.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

Review 8.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

9.  Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma.

Authors:  T Vu; W Gonsalves; S Kumar; A Dispenzieri; M Q Lacy; F Buadi; M A Gertz; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-23       Impact factor: 11.037

10.  Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Authors:  Meletios A Dimopoulos; Sagar Lonial; Darrell White; Philippe Moreau; Antonio Palumbo; Jesus San-Miguel; Ofer Shpilberg; Kenneth Anderson; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Hila Magen; Maria-Victoria Mateos; Andrew Belch; Donna Reece; Meral Beksac; Eric Bleickardt; Valerie Poulart; Jennifer Sheng; Oumar Sy; Jessica Katz; Anil Singhal; Paul Richardson
Journal:  Br J Haematol       Date:  2017-07-05       Impact factor: 6.998

View more
  51 in total

1.  Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Authors:  Abdullah S Al Saleh; Harsh V Parmar; Alissa Visram; Eli Muchtar; Francis K Buadi; Ronald S Go; Angela Dispenzieri; Prashant Kapoor; Rahma Warsame; Martha Q Lacy; David Dingli; Nelson Leung; Wilson I Gonsalves; Taxiarchis V Kourelis; Morie A Gertz; Robert A Kyle; S Vincent Rajkumar; Shaji K Kumar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-04-07

2.  Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.

Authors:  Sikander Ailawadhi; Kejal Parikh; Safiya Abouzaid; Zhou Zhou; Wenxi Tang; Zoe Clancy; Claudia Cheung; Zheng-Yi Zhou; Jipan Xie
Journal:  Blood Adv       Date:  2019-10-22

3.  Approach to the Older Adult With Multiple Myeloma.

Authors:  Roberto Mina; Sara Bringhen; Tanya M Wildes; Sonja Zweegman; Ashley E Rosko
Journal:  Am Soc Clin Oncol Educ Book       Date:  2019-05-17

4.  Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Authors:  Matthew Ho; Giada Bianchi; Kenneth C Anderson
Journal:  Expert Rev Precis Med Drug Dev       Date:  2020-02-24

5.  Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.

Authors:  Luyuan Zhang; Sinan Sun; Yumin Wang; Yongzhen Mo; Fang Xiong; Shanshan Zhang; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Hao Chen; Can Guo
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

6.  Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma.

Authors:  Wei Wang; Yinghua Xie; Xiyao Han; Yihan Liu; Pei Li
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

7.  Blood-based risk stratification for pre-malignant and symptomatic plasma cell neoplasms to improve patient management.

Authors:  María A Vasco-Mogorrón; José A Campillo; Adela Periago; Valentin Cabañas; Mercedes Berenguer; María C García-Garay; Lourdes Gimeno; María F Soto-Ramírez; María D Martínez-Hernández; Manuel Muro; Alfredo Minguela
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma.

Authors:  Brittany C Lipchick; Adam Utley; Zhannan Han; Sudha Moparthy; Dong Hyun Yun; Anna Bianchi-Smiraglia; David W Wolff; Emily Fink; Liang Liu; Cristina M Furdui; Jingyun Lee; Kelvin P Lee; Mikhail A Nikiforov
Journal:  Blood Adv       Date:  2021-04-13

9.  Rare subtype of multiple myeloma presenting as sacroiliac joint pain in an avid golfer: a case report.

Authors:  Melissa Belchos; Varsha Kumar; Carol Ann Weis
Journal:  J Can Chiropr Assoc       Date:  2020-12

10.  Lebanese Real-World Experience in Treating Multiple Myeloma: A Multicenter Retrospective Study.

Authors:  Fadi Nasr; Ahmad Al Ghoche; Saada Diab; Lewis Nasr; Emmanuel Ammanouil; Christelle Riachy; Souheil Hallit; Georges Chahine
Journal:  Leuk Res Rep       Date:  2021-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.